Paper39265169
Activating pyruvate kinase improves red blood cell integrity by reducing band 3 tyrosine phosphorylation.
Le K and 13 others. Blood Adv, 2024. Cited by 11 papers, by iCite.
Cite this record
ConductScience Library. Activating pyruvate kinase improves red blood cell integrity by reducing band 3 tyrosine phosphorylation. Papers, record 39265169. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39265169
- Disease
- sickle cell disease163 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Activating pyruvate kinase improves red blood cell integrity by reducing band 3 tyrosine phosphorylation.
- PubMed
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Erythrocytes | Major topic |
| Anion Exchange Protein 1, Erythrocyte | Major topic |
| Pyruvate Kinase | Major topic |
| Humans | |
| Phosphorylation | |
| Anemia, Sickle Cell | |
| Adenosine Triphosphate | |
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | |
| Ankyrins | |
| Tyrosine | |
| Enzyme Activation |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT04000165 | A Dose-Finding Study of AG-348 in Sickle Cell Disease | Derived from the trial | Yes |
Source ClinicalTrials.gov
References38
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 20455701 | Sickle cell biomechanics. | Annu Rev Biomed Eng | 2010 | https://conductscience.org/library/papers/20455701 | PubMed |
| 2 | 17576811 | Double knockouts reveal that protein tyrosine phosphatase 1B is a physiological target of calpain-1 in platelets. | Mol Cell Biol | 2007 | https://conductscience.org/library/papers/17576811 | PubMed |
| 3 | 36512028 | A robust fluorescence-based assay for human erythrocyte Ca++ efflux suitable for high-throughput inhibitor screens. | Eur Biophys J | 2023 | https://conductscience.org/library/papers/36512028 | PubMed |
| 4 | 37934880 | One-year safety and efficacy of mitapivat in sickle cell disease: follow-up results of a phase 2, open-label study. | Blood Adv | 2023 | https://conductscience.org/library/papers/37934880 | PubMed |
| 5 | 5549196 | The effect of 2,3-DPG on the sickling phenomenon. | Blood | 1971 | https://conductscience.org/library/papers/5549196 | PubMed |
| 6 | 7120411 | Oxygen binding by sickle cell hemoglobin polymers. | J Mol Biol | 1982 | https://conductscience.org/library/papers/7120411 | PubMed |
| 7 | 2393711 | 2,3-Diphosphoglycerate and intracellular pH as interdependent determinants of the physiologic solubility of deoxyhemoglobin S. | Blood | 1990 | https://conductscience.org/library/papers/2393711 | PubMed |
| 8 | 35964609 | Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion dependent α-thalassaemia or β-thalassaemia: an open-label, multicentre, phase 2 study. | Lancet | 2022 | https://conductscience.org/library/papers/35964609 | PubMed |
| 9 | 5443181 | Effect of 2,3-diphosphoglycerate on oxygen affinity of blood in sickle cell anemia. | J Clin Invest | 1970 | https://conductscience.org/library/papers/5443181 | PubMed |
| 10 | 15866743 | Calcium-dependent human erythrocyte cytoskeleton stability analysis through atomic force microscopy. | J Struct Biol | 2005 | https://conductscience.org/library/papers/15866743 | PubMed |
| 11 | 28248201 | Intravascular hemolysis and the pathophysiology of sickle cell disease. | J Clin Invest | 2017 | https://conductscience.org/library/papers/28248201 | PubMed |
| 12 | 32346864 | Inhibition of Band 3 tyrosine phosphorylation: a new mechanism for treatment of sickle cell disease. | Br J Haematol | 2020 | https://conductscience.org/library/papers/32346864 | PubMed |
| 13 | 22197026 | Deoxygenation-induced and Ca(2+) dependent phosphatidylserine externalisation in red blood cells from normal individuals and sickle cell patients. | Cell Calcium | 2012 | https://conductscience.org/library/papers/22197026 | PubMed |
| 14 | 9109401 | Erythrocyte thiol status regulates band 3 phosphotyrosine level via oxidation/reduction of band 3-associated phosphotyrosine phosphatase. | FEBS Lett | 1997 | https://conductscience.org/library/papers/9109401 | PubMed |
| 15 | 8223493 | Calpain-catalyzed cleavage and subcellular relocation of protein phosphotyrosine phosphatase 1B (PTP-1B) in human platelets. | EMBO J | 1993 | https://conductscience.org/library/papers/8223493 | PubMed |
| 16 | 11698299 | Deoxygenation of sickle cells stimulates Syk tyrosine kinase and inhibits a membrane tyrosine phosphatase. | Blood | 2001 | https://conductscience.org/library/papers/11698299 | PubMed |
| 17 | 35576529 | A phase 1 dose escalation study of the pyruvate kinase activator mitapivat (AG-348) in sickle cell disease. | Blood | 2022 | https://conductscience.org/library/papers/35576529 | PubMed |
| 18 | 9491367 | The structure and function of band 3 (AE1): recent developments (review). | Mol Membr Biol | 1997 | https://conductscience.org/library/papers/9491367 | PubMed |
| 19 | 17138828 | The effect of deoxygenation on whole-cell conductance of red blood cells from healthy individuals and patients with sickle cell disease. | Blood | 2007 | https://conductscience.org/library/papers/17138828 | PubMed |
| 20 | 14717789 | Reactive oxygen species and phosphatidylserine externalization in murine sickle red cells. | Br J Haematol | 2004 | https://conductscience.org/library/papers/14717789 | PubMed |
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 11 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42348606 | A high-throughput inhibitor screen for the erythrocyte plasma membrane Ca++ ATPase. | PLoS One | 2026 | https://conductscience.org/library/papers/42348606 | PubMed |
| 41978829 | Post-translational Modifications in Proteins: Prediction Methods, Biological Functions, and Diseases. | MedComm (2020) | 2026 | https://conductscience.org/library/papers/41978829 | PubMed |
| 41809202 | Long-term mitapivat treatment is safe and efficacious in patients with sickle cell disease. | Blood Red Cells Iron | 2025 | https://conductscience.org/library/papers/41809202 | PubMed |
| 41557517 | Pyruvate kinase deficiency modifies sickle hemoglobin carrier and sickle cell disease phenotypes in mice. | JCI Insight | 2026 | https://conductscience.org/library/papers/41557517 | PubMed |
| 40829689 | SIRPα extracellular domain shed from neutrophils by ADAM10 aggravates sepsis via initiating nitric oxide release from erythrocyte. | J Adv Res | 2026 | https://conductscience.org/library/papers/40829689 | PubMed |
| 39769244 | Epicatechin Influence on Biochemical Modification of Human Erythrocyte Metabolism and Membrane Integrity. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39769244 | PubMed |
| 38118071 | Recent developments in the use of pyruvate kinase activators as a new approach for treating sickle cell disease. | Blood | 2024 | https://conductscience.org/library/papers/38118071 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ANK1 | 286 | PubTator's text mining | https://conductscience.org/library/genes/286 | NCBI Gene |
| PTPN1 | 5770 | PubTator's text mining | https://conductscience.org/library/genes/5770 | NCBI Gene |
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| MITAPIVAT | CHEMBL4299940 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL4299940 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39265169
GET https://conductscience.org/api/papers/v1/39265169/references?page=2